Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 9/20 | 0.43 |
| ▸ | JAK2 | O60674 | 9/20 | 0.42 |
| ▸ | TYMS | P04818 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457352 | 0.88 | JAK2 (0.43) | CHEK1JAK2TYMS | |
| SCHEMBL2457841 | 0.81 | JAK2 (0.50) | CHEK1JAK2TYMS | |
| SCHEMBL2460685 | 0.76 | JAK2 (0.44) | CHEK1JAK2TYMS | |
| SCHEMBL2462573 | 0.73 | JAK2 (0.53) | CHEK1JAK2TYMS | |
| SCHEMBL2457900 | 0.72 | JAK2 (0.75) | CHEK1JAK2 | |
| SCHEMBL2456351 | 0.71 | CHEK1 (0.51) | CHEK1JAK2TYMS | |
| SCHEMBL2460761 | 0.69 | JAK2 (0.49) | CHEK1JAK2TYMS | |
| SCHEMBL2460195 | 0.69 | CHEK1 (0.51) | CHEK1JAK2TYMS | |
| SCHEMBL2457862 | 0.66 | CHEK1 (0.48) | CHEK1JAK2TYMS | |
| SCHEMBL2455666 | 0.66 | JAK2 (0.53) | CHEK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134346-B1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME (US) | 2011-09-21 | — | — | EP | claimed |
| US-20100160309-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | claimed |
| US-8329722-B2 | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2134346-B1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20100160309-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160309-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | JAK2, PDK1, JAK1 | CHEK1 657/4885JAK2 1/4885TYMS 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.